茅娅男;尤志学;

• 1:南京医科大学第一临床医学院
• 2:南京医科大学第一附属医院妇科

摘要(Abstract)：

2020年美国阴道镜和子宫颈病理学会(ASCCP)发布了2019版基于风险的子宫颈癌筛查异常及癌前病变管理共识指南(简称2019版指南),2019版指南与以前版本的主要区别在于:从基于筛查结果的"同等风险,同等管理",改为"基于风险",即通过了解当前筛查结果和既往病史的个体化管理,提高管理的准确性。对于进展子宫颈癌(以CINⅢ+的5年风险作为替代)高风险者,更频繁的监测、阴道镜检查和治疗,而对较低风险者可推迟行阴道镜检查,以更长的监测间隔进行随访,当风险足够低时,回归常规筛查。本文就该指南中子宫颈癌筛查结果异常的相关管理进行解读。

关键词(KeyWords)： 指南;宫颈癌筛查;管理

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 茅娅男;尤志学;

DOI: 10.13283/j.cnki.xdfckjz.2021.01.011

参考文献(References)：

• [1]Perkins RB,Guido RS,Castle PE,et al.2019 ASCCP riskbased management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors[J].JLower Genit Tract Dis,2020,24(2):102-131
• [2]Huh WK,Ault KA,Chelmow D,et al.Use of primary highrisk human papillomavirus testing for cervical cancer screening:interim clinical guidance[J].Gynecol Oncol,2015,136(2):178-182
• [3]Fontham ETH,Wolf AMD,Church TR,et al.Cervical cancer screening for individuals at average risk:2020 guideline update from the American Cancer Society[J].CA Cancer JClin,2020[Epub ahead of print]
• [4]Egemen D,Cheung LC,Chen X,et al.Risk estimates supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines[J].J Low Genit Tract Dis,2020,24(2):132-143
• [5]Demarco M,Egemen D,Raine-Bennett TR,et al.A study of partial human papillomavirus genotyping in support of the 2019 ASCCP risk-based management consensus guidelines[J].J Low Genit Tract Dis,2020,24(2):144-147
• [6]Meijer CJ,Berkhof J,Castle PE,et al.Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older[J].Int J Cancer,2009,124(3):516-520
• [7]Ritu N,David CW.The Bethesda system for reporting cervical cytology[M].3rd ed.Switzerland:Springer International Publishing,2015:193-237
• [8]Cervical Cancer Screening Guidelines Working Party.National Cervical Screening Program:Guidelines for the management of screen-detected abnormalities,screening in specific populations and investigation of abnormal vaginal bleeding[EB/OL].Sydney:Cancer Council Australia,2020[2020-08-16].https://wiki.cancer.org.au/australia/Guidelines:Cervical_cancer/Screening
• [9]Sultana F,English DR,Simpson JA,et al.High-grade cervical abnormalities and cervical cancer in women following a negative Pap smear with and without an endocervical component:a cohort study with 10 years of follow-up[J].Int J Cancer,2014,135(5):1213-1219
• [10]Polanco Jacome EC,Maerki J,Chau K,et al.Lack of transformation zone in cervical Pap tests,should it be a concern?A quality assurance initiative[J].Diagn Cytopathol,2018,46(7):584-588
• [11]Katki HA,Kinney WK,Fetterman B,et al.Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology:a populationbased study in routine clinical practice[J].Lancet Oncol,2011,12(7):663-672
• [12]Katki HA,Schiffman M,Castle PE,et al.Five-year risk of recurrence after treatment of CIN 2,CIN 3,or AIS:performance of HPV and Pap cotesting in posttreatment management[J].J Low Genit Tract Dis,2013,17(5 Suppl 1):S78-S84
• [13]Saslow D,Solomon D,Lawson HW,et al.American Cancer Society,American Society for Colposcopy and Cervical Pathology,and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.ACS-ASCCP-ASCP Cervical Cancer Guideline Committee[J].CA Cancer J Clin,2012,62(3):147-172
• [14]Katki HA,Schiffman M,Castle PE,et al.Five-year risks of CIN 3+and cervical cancer among women who test Pap-negative but are HPV-positive[J].J Low Genit Tract Dis,2013,17(5 Suppl 1):S56-S63
• [15]Vicari M,Guidobaldi L,Perrella E,et al.Morphometric analysis of atypical glandular cells correctly classifies normal,reactive,and atypical cells in cervical smears[J].Diagn Cytopathol,2020,48(1):10-16
• [16]Zhao C,Florea A,Onisko A,Austin RM.Histologic follow-up results in 662 patients with Pap test findings of atypical glandular cells:results from a large academic womens hospital laboratory employing sensitive screening methods[J].Gynecol Oncol,2009,114(3):383-389
• [17]Verdoodt F,Jiang X,Williams M,et al.High-risk HPVtesting in the management of atypical glandular cells:Asystematic review and meta-analysis[J].Int J Cancer,2016,138(2):303-310
• [18]Scheiden R,Wagener C,Knolle U,et al.Atypical glandular cells in conventional cervical smears:incidence and follow-up[J].BMC Cancer,2004,4:37
• [19]Kim MK,Lee YK,Hong SR,et al.Clinicopathological significance of atypical glandular cells on cervicovaginal Pap smears[J].Diagn Cytopathol,2017,45 (10):867-872
• [20]钱敏，尤志学，姚芳芳，等．阴道镜直视下宫颈活检诊断CIN1中漏诊高级别病变的分析[J]．中国妇产科临床杂志，2013,14(5):403-405
• [21]Katki HA,Gage JC,Schiffman M,et al.Follow-up testing after colposcopy:five-year risk of CIN 2+after a colposcopic diagnosis of CIN 1 or less[J].Low Genit Tract Dis,2013,17(5 Suppl 1):S69-S77
• [22]王荣敏，李雪洁，钱敏，等．CINI的转归及p16(INK4a)蛋白表达在分流CINI中的临床意义[J]．中华妇产科杂志，2015,50(3):210-215
• [23]Castle PE,Gage JC,Wheeler CM,et al.The clinical meaning of a cervical intraepithelial neoplasia grade 1biopsy[J].Obstet Gynecol,2011,118(6):1222-1229
• [24]Hariri S,Unger ER,Sternberg M,et al.Prevalence of genital human papillomavirus among females in the United States,the National Health and Nutrition Examination Survey,2003-2006[J].J Infect Dis,2011,204(4):566-573
• [25]Benard VB,Watson M,Castle PE,et al.Cervical carcinoma rates among young females in the United States[J].Obstet Gynecol,2012,120(5):1117-1123
• [26]Drolet M,Benard E,Boily MC,et al.Population-level impact and herd effects following human papillomavirus vaccination programmes:a systematic review and meta-analysis[J].Lancet Infect Dis,2015,15(5):565-580
• [27]Moore G,Fetterman B,Cox JT,et al.Lessons from practice:risk of CIN 3 or cancer associated with an LSIL or HPV-positive ASC-US screening result in women aged 21to 24[J].J Low Genit Tract Dis,2010,14(2):97-102
• [28]Katki HA,Schiffman M,Castle PE,et al.Five-year risk of CIN 3+to guide the management of women aged 21 to 24years[J].J Low Genit Tract Dis,2013,17(5 Suppl 1):S64-S68
• [29]Ryu KJ,Lee S,Min KJ,et al.Management of atypical squamous cells of undetermined significance or lowgrade squamous intraepithelial lesions of the uterine cervix with human papilloma virus infection among young women aged less than 25 years[J].Diagn Cytopathol,2016,44(12):959-963
• [30]Chapman CL,Harris AL.Cervical cancer screening for women living with HIV[J].Nurs Womens Health,2016,20(4):392-398
• [31]Robbins HA,Strickler HD,Massad LS,et al.Cervical cancer screening intervals and management for women living with HIV:a risk benchmarking approach[J].AIDS,2017,31(7):1035-1044
• [32]Moscicki AB,Flowers L,Huchko MJ,et al.Guidelines for cervical cancer screening in immunosuppressed women without HIV infection[J].J Low Genit Tract Dis,2019,23(2):87-101
• [33]Stokes-Lampard H,Wilson S,Waddell C,et al.Vaginal vault smears after hysterectomy for reasons other than malignancy:a systematic review of the literature[J].BJOG,2006,113(12):1354-1365
• [34]Khan MJ,Massad LS,Kinney W,et al.A common clinical dilemma:Management of abnormal vaginal cytology and human papillomavirus test results[J].Gynecol Oncol,2016,141(2):364-370
• [35]Cong Q,Song Y,Wang Q,et al.A retrospective study of cytology,high-risk hpv,and colposcopy results of vaginal intraepithelial neoplasia patients[J].Biomed Res Int,2018,2018:5894801